Company news

Niagen Bioscience, Inc. news in 2022

Niagen Bioscience, Inc.'s news releases, calls and decks from 2022, newest first.

View company

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

November 10, 2022

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

October 25, 2022

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

October 23, 2022

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

October 10, 2022

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

October 2, 2022

Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

September 18, 2022

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

August 31, 2022

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

August 14, 2022

ChromaDex Corporation Reports Second Quarter 2022 Financial Results

August 9, 2022

ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

July 6, 2022

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

June 14, 2022

ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

June 9, 2022

ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference

June 6, 2022

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

June 1, 2022

ChromaDex to Present at the LD Micro Invitational

May 31, 2022

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

May 16, 2022

ChromaDex Corporation Reports First Quarter 2022 Financial Results

May 11, 2022

ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 28, 2022

ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

April 21, 2022

ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

March 15, 2022

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

March 8, 2022

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)

March 1, 2022

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside

February 8, 2022

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

January 30, 2022

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

January 24, 2022

ChromaDex and Designs for Health Partner for New Product Development on Niagen®

January 19, 2022

Calls in 2022

Decks in 2022